News
-
-
COMMUNIQUÉ DE PRESSE
Activité du 3ème trimestre 2025 - Netgem poursuit le déploiement de ses relais de croissance et confirme son objectif 2025 d'amélioration des revenus récurrents et du résultat opérationnel
Netgem poursuit le déploiement de ses relais de croissance et confirme son objectif 2025 d'amélioration des revenus récurrents et du résultat opérationnel. Nouveaux produits et accords avec Vialis et 2K Games renforcent sa position sur les marchés du Cloud Gaming et des chaînes FAST -
COMMUNIQUÉ DE PRESSE
Business Update Q3 2025 - Netgem continues to deploy its growth drivers and confirms its 2025 objective of improving recurring revenues and operating profit
Netgem provides a business update for Q3 2025, focusing on growth drivers, new product launches, strategic agreements, and innovation in Cloud Gaming, FAST channels, and AI-enriched media services -
-
-
-
-
COMMUNIQUÉ DE PRESSE
ABB Ltd: ABB names Christian Nilsson to succeed Timo Ihamuotila as CFO
ABB appoints Christian Nilsson as CFO, succeeding Timo Ihamuotila. Nilsson to join Executive Committee on February 1, 2026. CEO Morten Wierod acknowledges Ihamuotila's contribution and welcomes Nilsson's leadership -
COMMUNIQUÉ DE PRESSE
Year-on-year third quarter sales growth of 23% remains strong as global uncertainties continue to weigh on order intake; strong FX headwinds persist
VAT Group AG reports 23% sales growth in Q3 2025 despite challenges; outlook for 2025 remains positive with higher expected results -
COMMUNIQUÉ DE PRESSE
Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties
